- Home
- NEGG vs GOSS Comparison
NEGG vs GOSS Comparison
Compare NEGG & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEGG
- GOSS
- Stock Information
- Founded
- NEGG 2001
- GOSS 2015
- Country
- NEGG United States
- GOSS United States
- Employees
- NEGG N/A
- GOSS N/A
- Industry
- NEGG Other Specialty Stores
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- NEGG Consumer Discretionary
- GOSS Health Care
- Exchange
- NEGG Nasdaq
- GOSS Nasdaq
- Market Cap
- NEGG 186.1M
- GOSS 212.8M
- IPO Year
- NEGG 2010
- GOSS 2019
- Fundamental
- Price
- NEGG $0.45
- GOSS $1.40
- Analyst Decision
- NEGG
- GOSS Strong Buy
- Analyst Count
- NEGG 0
- GOSS 5
- Target Price
- NEGG N/A
- GOSS $9.20
- AVG Volume (30 Days)
- NEGG 898.0K
- GOSS 1.6M
- Earning Date
- NEGG 08-29-2024
- GOSS 03-04-2025
- Dividend Yield
- NEGG N/A
- GOSS N/A
- EPS Growth
- NEGG N/A
- GOSS N/A
- EPS
- NEGG N/A
- GOSS N/A
- Revenue
- NEGG $1,391,833,000.00
- GOSS $105,322,000.00
- Revenue This Year
- NEGG $6.01
- GOSS N/A
- Revenue Next Year
- NEGG N/A
- GOSS N/A
- P/E Ratio
- NEGG N/A
- GOSS N/A
- Revenue Growth
- NEGG N/A
- GOSS N/A
- 52 Week Low
- NEGG $0.39
- GOSS $0.50
- 52 Week High
- NEGG $1.32
- GOSS $1.60
- Technical
- Relative Strength Index (RSI)
- NEGG 49.23
- GOSS 67.09
- Support Level
- NEGG $0.44
- GOSS $1.37
- Resistance Level
- NEGG $0.54
- GOSS $1.55
- Average True Range (ATR)
- NEGG 0.03
- GOSS 0.13
- MACD
- NEGG 0.00
- GOSS 0.03
- Stochastic Oscillator
- NEGG 32.54
- GOSS 75.81
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.